

Website news release

Latest update on TIES Solution - January 2018

Message from CEO Ostomycure Dr Benedict Broenniman M.D.

In consultation with our Notified Body, it has been decided to collect additional clinical data in a new clinical study at specialized colorectal units in the UK & Sweden. The previous sponsored studies have shown the implant's short and long-term safety profile. The aim of the new clinical study "TIES-C03" is to evaluate the long-term performance, safety, and impact of the TIES solution on quality of life. The patient's perspective on the use of the TIES solution for controlled bowel emptying will also be included in the assessment.

"We know that TIES Solution is a safe concept for ileostomy patients. What we would like to establish is a scientific base which will prove our product claims in a small number of clinical centers," says CEO Ostomycure Dr. med. Benedict Broenniman.

The new study is planned to start in April 2018 with follow-up throughout 2019. The investigators are Associate Professor Karin Strigård and Professor Ulf Gunnarsson in Umeå (Sweden), and Professor David Jayne in Leeds (UK).